Elicio Therapeutics Enters Material Definitive Agreement

Ticker: ELTX · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1601485

Elicio Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyElicio Therapeutics, Inc. (ELTX)
Form Type8-K
Filed DateMar 18, 2024
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.01, $5.81, $6.0 million
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, company-name-change

TL;DR

Elicio Therapeutics just signed a big deal, filing an 8-K today.

AI Summary

Elicio Therapeutics, Inc. announced on March 18, 2024, that it has entered into a Material Definitive Agreement. The company, formerly known as Angion Biomedica Corp. until February 28, 2014, is headquartered in Boston, Massachusetts.

Why It Matters

This filing indicates a significant new contract or partnership for Elicio Therapeutics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks related to partnerships, obligations, and financial commitments.

Key Numbers

  • 001-39990 — SEC File Number (Identifies the company's filing history)
  • 11-3430072 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • Elicio Therapeutics, Inc. (company) — Registrant
  • Angion Biomedica Corp. (company) — Former company name
  • March 18, 2024 (date) — Date of report
  • February 28, 2014 (date) — Date of name change
  • Boston, Massachusetts (location) — Company headquarters

FAQ

What is the nature of the Material Definitive Agreement?

The filing does not specify the details of the Material Definitive Agreement, only that one has been entered into as of March 18, 2024.

When did Elicio Therapeutics change its name?

Elicio Therapeutics, Inc. was formerly known as Angion Biomedica Corp. until February 28, 2014.

Where is Elicio Therapeutics, Inc. headquartered?

The company's principal executive offices are located at 451 D Street, 5th Floor, Boston, Massachusetts 02210.

What is the SEC file number for Elicio Therapeutics, Inc.?

The SEC file number for Elicio Therapeutics, Inc. is 001-39990.

What is the primary business of Elicio Therapeutics, Inc.?

Elicio Therapeutics, Inc. operates in the Pharmaceutical Preparations industry, SIC code 2834.

Filing Stats: 1,307 words · 5 min read · ~4 pages · Grade level 13 · Accepted 2024-03-18 08:05:32

Key Financial Figures

  • $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Glo
  • $5.81 — urchase price per Pre-Funded Warrant of $5.81 (the "Offering"). The gross proceeds to
  • $6.0 million — ds to the Company will be approximately $6.0 million. The closing of the Offering is expecte

Filing Documents

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On March 18, 2024, Elicio Therapeutics, Inc. (the "Company") entered into a Subscription Agreement (the "Subscription Agreement") with GKCC, LLC (the "Purchaser"), an entity controlled by a member of the board of directors of the Company, providing for the issuance and sale by the Company to the Purchaser of pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,032,702 shares of common stock, par value $0.01 per share, of the Company ("Common Stock"), at a purchase price per Pre-Funded Warrant of $5.81 (the "Offering"). The gross proceeds to the Company will be approximately $6.0 million. The closing of the Offering is expected to take place on March 19, 2024, subject to the satisfaction of customary closing conditions (the "Closing Date"). The Company intends to use the proceeds of the Offering for the advancement of its development pipeline, as well as for working capital and general corporate purposes. The Pre-Funded Warrants will be exercisable at any time on or after the Closing Date at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrants, provided, however, that the Pre-Funded Warrants may not be exercised if, after giving effect or immediately prior to such exercise, the Purchaser, together with its affiliates and any other persons whose beneficial ownership of shares of Common Stock would be aggregated with the Purchaser for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own more than 19.99% (the "Maximum Percentage") of the total number of issued and outstanding shares of Common Stock or voting power of the Company following such exercise, unless Stockholder Approval (defined below) has been obtained. Pursuant to the Subscription Agreement, the Company is obligated, among other things, to file a registration statement with the U.S. Securities and Exchange Commission (th

02 Unregistered Sale of Equity Securities

Item 3.02 Unregistered Sale of Equity Securities. The information under Item 1.01 of this Current Report on Form 8-K related to the Pre-Funded Warrants and Pre-Funded Warrant Shares is incorporated herein by reference.

01 Other Events

Item 8.01 Other Events. On March 18, 2024, the Company issued a press release announcing the Offering, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 10.1 Subscription Agreement, dated as of March 18, 2024, by and between Elicio Therapeutics, Inc. and GKCC, LLC. 10.2 Form of Pre-Funded Warrant. 99.1 Press Release of Elicio Therapeutics, Inc., dated March 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: March 18, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.